{"DataElement":{"publicId":"6941964","version":"1","preferredName":"Baseline Measurable Tumor RECIST Type","preferredDefinition":"The kind of lesion or lymph node identified at baseline that meets the minimum size requirements as defined in the Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).","longName":"TUBMTRTP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6941807","version":"1","preferredName":"Tumor Identifier Domain Baseline Measurable Neoplasm","preferredDefinition":"A domain that represents the data that uniquely identifies tumors._A starting point to which things may be compared._Capable of being measured._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"6607938v1.0:6941805v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6607938","version":"1","preferredName":"Tumor Identifier Domain","preferredDefinition":"A domain that represents the data that uniquely identifies tumors.","longName":"C106577","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Identifier Domain","conceptCode":"C106577","definition":"A domain that represents the data that uniquely identifies tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F1D6F05-C099-2E3D-E053-F662850A5D84","latestVersionIndicator":"Yes","beginDate":"2019-01-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-01-10","modifiedBy":"ONEDATA","dateModified":"2019-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6941805","version":"1","preferredName":"Baseline Measurable Neoplasm","preferredDefinition":"A starting point to which things may be compared.:Capable of being measured.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C25213:C37894:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Baseline","conceptCode":"C25213","definition":"A starting point to which things may be compared.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Measurable","conceptCode":"C37894","definition":"Capable of being measured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"92C4810F-48B1-0E42-E053-F662850A5072","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"ONEDATA","dateModified":"2019-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"92C4810F-48C2-0E42-E053-F662850A5072","latestVersionIndicator":"Yes","beginDate":"2019-09-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-17","modifiedBy":"COOPERM","dateModified":"2020-06-04","changeDescription":"Created for CDISC aligned NCI CRF standards task. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3860635","version":"2","preferredName":"RECIST Measurable Type","preferredDefinition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com)._Something distinguishable as an identifiable class based on common qualities.","longName":"3860635v2.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"10","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Lesions with prior local treatment","valueDescription":"Lesion With Prior Local Therapy","ValueMeaning":{"publicId":"5946399","version":"1","preferredName":"Lesion With Prior Local Therapy","longName":"5946399","preferredDefinition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.: Used to indicate the presence of something or someone.: Earlier in time or order.: Any therapeutic procedure that targets, or is restricted to, a specific anatomical location.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Local Therapy","conceptCode":"C15687","definition":"Any therapeutic procedure that targets, or is restricted to, a specific anatomical location.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"580E6344-CBBA-08D5-E053-F662850AA0AA","latestVersionIndicator":"Yes","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"TAYLORT","dateModified":"2018-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580E6344-CBD3-08D5-E053-F662850AA0AA","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"ONEDATA","dateModified":"2017-08-31","deletedIndicator":"No"},{"value":"Cystic lesions","valueDescription":"Cyst Lesion","ValueMeaning":{"publicId":"3860637","version":"1","preferredName":"Cyst Lesion","longName":"3860637","preferredDefinition":"A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.: A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyst","conceptCode":"C2978","definition":"A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E469528A-7C14-269F-E040-BB89AD435850","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-20","modifiedBy":"TAYLORT","dateModified":"2018-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580E6344-CB12-08D5-E053-F662850AA0AA","beginDate":"2013-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"ONEDATA","dateModified":"2017-08-31","deletedIndicator":"No"},{"value":"Bone lesions","valueDescription":"Bone Lesion","ValueMeaning":{"publicId":"3860638","version":"1","preferredName":"Bone Lesion","longName":"3860638","preferredDefinition":"Connective tissue that forms the skeletal components of the body.: A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone","conceptCode":"C12366","definition":"The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E469528A-7C37-269F-E040-BB89AD435850","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-20","modifiedBy":"ONEDATA","dateModified":"2013-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580E6344-CB1C-08D5-E053-F662850AA0AA","beginDate":"2013-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"ONEDATA","dateModified":"2017-08-31","deletedIndicator":"No"},{"value":"Tumor lesions","valueDescription":"Neoplasm Lesion","ValueMeaning":{"publicId":"5946398","version":"1","preferredName":"Neoplasm Lesion","longName":"5946398","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.: A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"580E6344-CB92-08D5-E053-F662850AA0AA","latestVersionIndicator":"Yes","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580E6344-CBAB-08D5-E053-F662850AA0AA","beginDate":"2017-08-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"ONEDATA","dateModified":"2017-08-31","deletedIndicator":"No"},{"value":"Malignant lymph node","valueDescription":"Malignant Lymph Node","ValueMeaning":{"publicId":"3860655","version":"1","preferredName":"Malignant Lymph Node","longName":"3860655","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymph Node","conceptCode":"C12745","definition":"A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4697DB6-404C-DAA4-E040-BB89AD434B4A","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"580E6344-CBE7-08D5-E053-F662850AA0AA","beginDate":"2013-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"ONEDATA","dateModified":"2017-08-31","deletedIndicator":"No"},{"value":"Brain lesions","valueDescription":"Brain Lesion","ValueMeaning":{"publicId":"6471057","version":"1","preferredName":"Brain Lesion","longName":"6471057","preferredDefinition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.: A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brain","conceptCode":"C12439","definition":"An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77ACA5F5-9C9C-2546-E053-F662850A9133","latestVersionIndicator":"Yes","beginDate":"2018-10-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-10-07","modifiedBy":"TAYLORT","dateModified":"2018-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77ACA5F5-9CB5-2546-E053-F662850A9133","beginDate":"2018-10-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-10-07","modifiedBy":"ONEDATA","dateModified":"2018-10-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3272579","version":"1","preferredName":"Response Evaluation Criteria in Solid Tumors Type","preferredDefinition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com):Type; a subdivision of a particular kind of thing.","longName":"C49164:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response Evaluation Criteria in Solid Tumors","conceptCode":"C49164","definition":"Standard parameters to be used when documenting response of solid tumors to treatment; a set of published rules that define when cancer patients improve (\"respond\"), stay the same (\"stable\"), or worsen (\"progression\") during treatments. (from www.recist.com)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACEA336D-9BE1-9D02-E040-BB89AD43428D","latestVersionIndicator":"Yes","beginDate":"2011-09-14","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-09-14","modifiedBy":"ONEDATA","dateModified":"2011-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RECISTv1.1:Response Evaluation Criteria in Solid Tumors v1.1","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"580E6344-CAF0-08D5-E053-F662850AA0AA","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-08-31","modifiedBy":"KNABLEJ","dateModified":"2018-10-23","changeDescription":"10/23/18 jk chg reg status to Standard for RECIST defined PV list; do not add PVs without checking latest version of guideline.  10/7/18 jk added Breain lesion to support irRECIST PV list per RECIST FG recommendation. 8/31/17 tt VD versioned for changes to LN concepts, min/max length, and PVs per RECIST 1.1; transferred Context, added CSI and reg status per Round 5 finalization task.  6/19/16 removed qualifier concepts per current BP; released. jk 8/20/13 created for RECIST CRF module; values based on definitions in RECISTv1.1 guideline, section 3.1.1. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6921971","version":"1","longName":"CDISC Aligned Collection CDEs","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6921976","version":"1","longName":"RECISTv1.1 - CDISC Aligned","context":"NCI Standards"},{"publicId":"6921972","version":"1","longName":"RECIST - CDISC Aligned ","context":"NCI Standards"},{"publicId":"6921975","version":"1","longName":"irRECIST - CDISC Aligned","context":"NCI Standards"}]},{"publicId":"7434158","version":"1","longName":"CTEP CDISC Harmonization","context":"CTEP","ClassificationSchemeItems":[{"publicId":"7473993","version":"1","longName":"CTEP CDISC RECIST v1.1","context":"CTEP"}]}],"AlternateNames":[{"name":"BLMRLES","type":"Context Short Name","context":"NCI Standards"},{"name":"CTEP","type":"USED_BY","context":"CTEP"},{"name":"TR_TRORRES_MEASTYP","type":"CTEP CDISC CDE","context":"CTEP"}],"ReferenceDocuments":[{"name":"irRECIST","type":"Alternate Question Text","description":"Baseline measurable lesion type","url":null,"context":"NCI Standards"},{"name":"RECIST","type":"Alternate Question Text","description":"Baseline measurable lesion","url":null,"context":"NCI Standards"},{"name":"Baseline measurable lesion","type":"Preferred Question Text","description":"Baseline measurable lesion","url":null,"context":"NCI Standards"},{"name":"What is the measurable lesion type?","type":"Alternate Question Text","description":"What is the measurable lesion type?","url":null,"context":"CTEP"},{"name":"Measurable lesion type","type":"Alternate Question Text","description":"Measurable lesion type","url":null,"context":"CTEP"}],"origin":"NCI CRF Standards","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"92D66E09-7398-5FCD-E053-F662850AAB84","latestVersionIndicator":"Yes","beginDate":"2019-09-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-09-18","modifiedBy":"GDEEN","dateModified":"2023-02-13","changeDescription":"Created for CDISC aligned NCI Standard CRF task. mc 10.6.2020 Released for CTEP reuse. mc","administrativeNotes":"02.13.23_Set Reg Status to Standard for all CDISC Aligned content_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}